Float Short %

14.75

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

-2.69

EPS Last/This Y

0.77

EPS This/Next Y

-11.2

Price

15.88

Target Price

Analyst Recom

2.33

Performance Q

-21.06

Relative Volume

0.17

Beta

0.23

Ticker: MCRB

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	MCRB	16.78	0.18	0.01	12613
2025-12-10	MCRB	16.89	0.17	0.02	12644
2025-12-11	MCRB	17.29	0.17	0.31	12677
2025-12-12	MCRB	16.97	0.18	1.14	12697
2025-12-15	MCRB	15.81	0.18	0.76	12807
2025-12-16	MCRB	16.29	0.19	0.14	12918
2025-12-17	MCRB	15.36	0.19	0.58	12935
2025-12-18	MCRB	15.25	0.19	2.47	13057
2025-12-19	MCRB	14.94	0.20	0.39	13141
2025-12-22	MCRB	14.7	0.18	0.02	12166
2025-12-23	MCRB	14.95	0.18	0.07	12206
2025-12-26	MCRB	14.65	0.18	0.24	12225
2025-12-29	MCRB	14.99	0.18	0.11	12237
2025-12-30	MCRB	14.56	0.18	0.02	12277
2025-12-31	MCRB	14.87	0.18	0.00	12291
2026-01-02	MCRB	15.12	0.18	0.00	12287
2026-01-05	MCRB	15.18	0.18	3.36	12291
2026-01-06	MCRB	15.52	0.19	2.45	12465
2026-01-07	MCRB	15.79	0.19	0.27	12491
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	MCRB	16.78	27.3	-	0.77
2025-12-10	MCRB	16.89	27.3	-	0.77
2025-12-11	MCRB	17.21	27.3	-	0.77
2025-12-12	MCRB	17.07	27.3	-	0.77
2025-12-15	MCRB	15.90	27.3	-	0.77
2025-12-16	MCRB	15.90	27.3	-	0.77
2025-12-17	MCRB	15.42	27.3	-	0.77
2025-12-18	MCRB	15.16	27.3	-	0.77
2025-12-19	MCRB	14.87	27.3	-	0.77
2025-12-22	MCRB	14.76	27.3	-	0.77
2025-12-23	MCRB	15.01	27.3	-	0.77
2025-12-26	MCRB	14.74	27.3	-	0.77
2025-12-29	MCRB	14.92	27.3	-	0.77
2025-12-30	MCRB	14.50	27.3	-	0.77
2025-12-31	MCRB	14.84	27.3	-	0.77
2026-01-02	MCRB	15.09	27.3	-	0.77
2026-01-05	MCRB	15.18	27.3	-	0.77
2026-01-06	MCRB	15.45	27.3	-	0.77
2026-01-07	MCRB	15.88	27.3	-	0.77
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	MCRB	-0.12	-1.75	13.96
2025-12-10	MCRB	-0.12	-1.75	15.04
2025-12-11	MCRB	-0.12	-1.75	15.04
2025-12-12	MCRB	-0.12	-1.75	15.04
2025-12-15	MCRB	-0.12	-1.75	14.86
2025-12-16	MCRB	-0.13	-1.75	14.86
2025-12-17	MCRB	-0.13	-1.75	14.86
2025-12-18	MCRB	-0.13	-1.75	14.86
2025-12-19	MCRB	-0.13	-1.75	14.86
2025-12-22	MCRB	-0.13	-1.75	14.86
2025-12-23	MCRB	-0.13	-1.75	14.86
2025-12-26	MCRB	-0.13	-1.75	14.75
2025-12-29	MCRB	-0.13	-1.75	14.75
2025-12-30	MCRB	-0.13	-1.75	14.75
2025-12-31	MCRB	-0.13	-1.75	14.75
2026-01-02	MCRB	-0.13	-1.75	14.75
2026-01-05	MCRB	-0.13	-1.70	14.75
2026-01-06	MCRB	-0.13	-1.70	14.75
2026-01-07	MCRB	-0.13	-1.70	14.75
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.94

Avg. EPS Est. Current Quarter

-1.6

Avg. EPS Est. Next Quarter

-1.75

Insider Transactions

-0.13

Institutional Transactions

-1.7

Beta

0.23

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.3

Max Drawdown 5-Year %

-98.8

Target Price

P/E

26.12

Forward P/E

PEG

P/S

409.93

P/B

3.18

P/Free Cash Flow

EPS

0.61

Average EPS Est. Cur. Y

0.77

EPS Next Y. (Est.)

-10.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

1536.75

Relative Volume

0.17

Return on Equity vs Sector %

-14.7

Return on Equity vs Industry %

0.4

EPS 1 7Days Diff

-0.6

EPS 1 30Days Diff

-0.57

EBIT Estimation

Seres Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 103

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

stock quote shares MCRB – Seres Therapeutics, Inc. Stock Price stock today

news today MCRB – Seres Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MCRB – Seres Therapeutics, Inc. yahoo finance google finance

stock history MCRB – Seres Therapeutics, Inc. invest stock market

stock prices MCRB premarket after hours

ticker MCRB fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MCRB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y